Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology.

The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. 

In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

Immunovant

Arbutus Biopharma

RTW Investments

SoftBank Capital

Suvretta Capital Management

Viking Global Investors

Dainippon Sumitomo Pharma

Eventide

Fidelity

Fidelity Management and Research Company

Palantir Technologies

Patient Square Capital

SoftBank Vision Fund

Founders Fund

Dexcel Pharma

Novaquest Capital Management

QVT Financial

Roivant Sciences

Espero Biopharma is a biotechnology company focused on developing therapies for neurological and endocrine diseases.

Espero Biopharma

Denovo Biopharma is a biotechnology company specializing in the research and development of treatments for neurological and endocrine diseases.

Denovo Biopharma

Kallyope is a biotechnology company that focuses on developing therapies for neurological and endocrine diseases.

Kallyope

Acellera is a technology company specializing in computable drug discovery for the pharmaceutical industry.

Acellera

Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company focused on the development and commercialization of medicines for inflammation and immunology areas. The company utilizes a model called Vants to develop and commercialize its medicines and technologies, with a focus on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences Ltd.

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

financial_statements

network_onboarding

company_summary

signals

regulatory_analysis

industry_analysis

swot_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

news_advanced

news_impact_assignment_advanced

news_processing_advanced

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom	Mar 8, 2024 1:10 AM	dcb52328
news impact assignment basic	general	Mar 8, 2024 1:10 AM	237e485d
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 1:10 AM	673ea826
company summary	general
signals	general	Mar 8, 2024 1:10 AM	155f5fee
news advanced	general
news impact assignment advanced	general
news processing advanced	general
peers	general	Mar 8, 2024 1:10 AM	9eff8644
news basic	general	Mar 8, 2024 1:10 AM	39a632b8
events	markdown
bundesanzeiger	filings
financial statements	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
swot analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
customer profile	customers

COM:ROIVANT

Roivant Sciences Ltd.

Last Close

10.74

26/07 20:00

Market Cap

8.31B

Beta: -

Volume Today

3.58M

Avg: -